Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.
Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus.
The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors.
It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 27, 24 | -0.22 Increased by +58.49% | -0.19 Decreased by -15.79% |
| Mar 12, 24 | -0.22 Increased by +56.86% | -0.27 Increased by +18.52% |
| Nov 2, 23 | -0.41 Increased by +6.82% | -0.47 Increased by +12.77% |
| Aug 3, 23 | -0.43 Increased by +8.51% | -0.49 Increased by +12.24% |
| May 4, 23 | -0.53 Increased by +36.90% | -0.48 Decreased by -10.42% |
| Mar 9, 23 | -0.51 Increased by +42.70% | -0.47 Decreased by -8.51% |
| Nov 2, 22 | -0.44 Increased by +43.59% | -0.58 Increased by +24.14% |
| Aug 4, 22 | -0.47 Increased by +40.51% | -0.67 Increased by +29.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 986.00 K Decreased by -63.79% | -34.86 M Decreased by -51.88% | Decreased by -3.54 K% Decreased by -319.43% |
| Dec 31, 23 | 2.68 M Decreased by -24.20% | -27.89 M Decreased by -27.44% | Decreased by -1.04 K% Decreased by -68.13% |
| Sep 30, 23 | 3.24 M Decreased by -21.12% | -18.04 M Increased by +3.11% | Decreased by -556.99% Decreased by -22.82% |
| Jun 30, 23 | 6.89 M Increased by +86.46% | -18.79 M Increased by +5.69% | Decreased by -272.89% Increased by +49.42% |
| Mar 31, 23 | 2.72 M Increased by +5.91% | -22.95 M Increased by +35.55% | Decreased by -843.00% Increased by +39.14% |
| Dec 31, 22 | 3.54 M Increased by +863.76% | -21.89 M Increased by +41.97% | Decreased by -618.77% Increased by +93.98% |
| Sep 30, 22 | 4.11 M Increased by +167.14% | -18.62 M Increased by +43.78% | Decreased by -453.51% Increased by +78.96% |
| Jun 30, 22 | 3.69 M Increased by +139.03% | -19.92 M Increased by +33.18% | Decreased by -539.51% Increased by +72.05% |